EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
作者：
Douillard, Jean-Yves [1 ]
Ostoros, Gyula [2 ]
Cobo, Manuel [3 ]
Ciuleanu, Tudor [4 ]
Mccormack, Rose [7 ]
Webster, Alan [5 ]
Milenkova, Tsveta [6 ]
机构：
[1] Ico R Gauducheau, St Herblain, France
[2] Koranyi Natl Inst Tb & Pulmonol, Budapest, Hungary
[3] Hru Carlos Haya, Malaga, Spain
[4] Prof Dr Ion Chiricuta Inst Oncol, Cluj Napoca, Romania
[5] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[6] Astrazeneca, Res & Dev, Cambridge, England
[7] Astrazeneca, Personalised Healthcare, Luton, Beds, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR mutation; gefitinib; NSCLC; Caucasian; circulating-free DNA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-020
引用
收藏
页码：S1194 / S1195
页数：2
相关论文
共 50 条
  • [21] AN ADMINISTRATION TIMING AND DOSAGE OF THE GEFITINIB IN THE ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
    Fujimoto, Sakae
    Miura, Yosuke
    Yoshida, Tsutomu
    Fujita, Atsushi
    Minato, Kouichi
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1164 - S1164
  • [22] FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY
    Wu, Yi-Long
    Liam, Chong-Kin
    Zhou, Caicun
    Wu, Gang
    Liu, Xiaoqing
    Zhong, Zhaoyang
    Lu, Shun
    Cheng, Ying
    Han, Baohui
    Chen, Lei
    Zhu, Yunzhong
    Qin, Shukui
    Huang, Cheng
    Pan, Hongming
    Liang, Houjie
    Li, Enxiao
    How, Soon Hin
    Jiang, Guoliang
    Cherry, Marie
    Fernando, Lynn
    Chen, Meng
    Zuo, Yunxia
    Ladrera, Guia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S603 - S604
  • [23] Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
    Laura Ortega-Granados, Ana
    Artal-Cortes, Angel
    Aguiar-Bujanda, David
    Oramas, Juana
    Luis Firvida, Jose
    De Castro, Javier
    Campillo Fuentes, Juana
    Gordo, Rocio
    Galan, Raquel
    Trigo, Jose
    ANTICANCER RESEARCH, 2019, 39 (03) : 1317 - 1328
  • [24] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [25] ERLOTINIB AFTER FAILURE OF GEFITINIB THERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH OR WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION
    Saito, Hiroshi
    Kimura, Tomoki
    Abe, Takashi
    Kondo, Masashi
    Ogasawara, Tomohiko
    Tanikawa, Yoshimasa
    Yokoyama, Toshihiko
    Kojima, Eiji
    Yamamoto, Masashi
    Suzuki, Ryujiro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1210 - S1211
  • [26] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues
    Gridelli, C.
    De Marinis, F.
    Di Maio, M.
    Cortinovis, D.
    Cappuzzo, F.
    Mok, T.
    LUNG CANCER, 2011, 72 (01) : 3 - 8
  • [27] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
  • [28] Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
    Lu, Shun
    Zhou, Jian-Ying
    Niu, Xiao-Min
    Zhou, Jian-Ya
    Jian, Hong
    Yin, Hong-Yan
    Guan, Sha
    Wang, Lin-Fang
    Li, Ke
    He, James
    Su, Wei-Guo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 839 - +
  • [29] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ASIAN AND EUROPEAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Novello, Silvia
    Mok, Tony
    Scagliotti, Giorgio
    Finkelstein, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1179 - S1179
  • [30] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schmid, S.
    Schar, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L.
    von Briel, T.
    Waibel, C.
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W. D.
    Siano, M.
    Boos, L.
    Britschgi, C.
    Fruh, M.
    LUNG CANCER, 2024, 187
12345